A phase II, randomized, open-label study to assess the efficacy of extended-dose schedule administration of darbepoetin alfa in cancer patients with chemotherapy-induced anemia

Lee Schwartzberg; Timothy Rearden; Lorrin Yee; Barry Mirtsching; Veena Charu; Hung Lam; Tom Lillie; Ronald Burkes; Peter Silberstein

A phase II, randomized, open-label study to assess the efficacy of extended-dose schedule administration of darbepoetin alfa in cancer patients with chemotherapy-induced anemia

Lee Schwartzberg, Timothy Rearden, Lorrin Yee, Barry Mirtsching, Veena Charu, Hung Lam, Tom Lillie, Ronald Burkes, Peter Silberstein

Internal Medicine

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Original language	English (US)
Pages (from-to)	22-23
Number of pages	2
Journal	Journal of Supportive Oncology
Volume	5
Issue number	4 SUPPL. 2
State	Published - Apr 2007

ASJC Scopus subject areas

Oncology
Pharmacology (medical)

Cite this

A phase II, randomized, open-label study to assess the efficacy of extended-dose schedule administration of darbepoetin alfa in cancer patients with chemotherapy-induced anemia. / Schwartzberg, Lee; Rearden, Timothy; Yee, Lorrin et al.
In: Journal of Supportive Oncology, Vol. 5, No. 4 SUPPL. 2, 04.2007, p. 22-23.

Research output: Contribution to journal › Article › peer-review

@article{880e7e8cf73d4b96b765a14fa9181f50,

title = "A phase II, randomized, open-label study to assess the efficacy of extended-dose schedule administration of darbepoetin alfa in cancer patients with chemotherapy-induced anemia",

author = "Lee Schwartzberg and Timothy Rearden and Lorrin Yee and Barry Mirtsching and Veena Charu and Hung Lam and Tom Lillie and Ronald Burkes and Peter Silberstein",

year = "2007",

month = apr,

language = "English (US)",

volume = "5",

pages = "22--23",

journal = "Journal of Supportive Oncology",

issn = "1544-6794",

publisher = "Biolink Communications, Inc.",

number = "4 SUPPL. 2",

}

TY - JOUR

T1 - A phase II, randomized, open-label study to assess the efficacy of extended-dose schedule administration of darbepoetin alfa in cancer patients with chemotherapy-induced anemia

AU - Schwartzberg, Lee

AU - Rearden, Timothy

AU - Yee, Lorrin

AU - Mirtsching, Barry

AU - Charu, Veena

AU - Lam, Hung

AU - Lillie, Tom

AU - Burkes, Ronald

AU - Silberstein, Peter

PY - 2007/4

Y1 - 2007/4

UR - http://www.scopus.com/inward/record.url?scp=34250615108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250615108&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:34250615108

SN - 1544-6794

VL - 5

SP - 22

EP - 23

JO - Journal of Supportive Oncology

JF - Journal of Supportive Oncology

IS - 4 SUPPL. 2

ER -

A phase II, randomized, open-label study to assess the efficacy of extended-dose schedule administration of darbepoetin alfa in cancer patients with chemotherapy-induced anemia

ASJC Scopus subject areas

Other files and links

Cite this